GeNeuro
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Chemin Du Pré-fleuri 3, Plan-les-Ouates,...Phone Number
+41 225524800Website
www.geneuro.comRevenue
-Stock Symbol
GNROIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About GeNeuro
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, SwitzerRead more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is GeNeuro your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if GeNeuro had a recent Job posting/layoffs
Earning: See what the market has to say on GeNeuro recently announced quarterly report
GeNeuro, which may be a good buyer, showed buying intent in Masked Content Topic
Check if GeNeuro has recently received funding, and reach out quickly before it becomes old news!
Check out if GeNeuro is spiking on competitors!
Product Launch: Get notified when GeNeuro launches new products
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at GeNeuro
Funding: Get notified immidiatlly once GeNeuro has new funding data
Recommended Actions
Reach out to Masked Content who joined GeNeuro as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
GeNeuro is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GeNeuro is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GeNeuro.
GeNeuro Tech Stack
A closer look at the technologies used by GeNeuro
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
GeNeuro News & Media
GENEURO SA (EPA:GNRO) | Inside Information / Other news releases - WebDisclosure
GeNeuro SA extends its definitive debt-restructuring moratorium until January 27, 2026, to explore strategic options and continue developing treatments for neurodegenerative and autoimmune diseasesGeNeuro SA Announces Renewal of Provisional Debt-Restructuring Moratorium
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimGeNeuro SA Obtains the Opening of Debt-Restructuring Proceedings | Business Wire
Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoim
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GeNeuro
Sign Up For FreeTo access detailed company insights
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase... Read More
